RALA and chronic myelogenous leukemia, BCR-ABL1 positive: Recipients of BMCs transformed with BCR-ABL from RalARosa26-Tg/+ donor mice (2.47%) showed significantly rapid CML development as compared to those receiving BMCs transformed using BCR-ABL from RalA+/+ donor mice (1.73%) (Figure 4F).